-
Mashup Score: 2Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer - 16 hour(s) ago
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber - 1 month(s) ago
Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber @romeerizwan @rlporter18 @danafarber #gyncsm #oncology https://t.co/UtDlmMOuvl
-
-
Mashup Score: 0ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer - 1 month(s) ago
Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer @WUSTLmed #gyncsm #oncology https://t.co/GDisEPIamY
-
-
Mashup Score: 0ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer - 1 month(s) ago
Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer @WUSTLmed #gyncsm #oncology https://t.co/GDisEPIamY
-
-
Mashup Score: 2ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer - 2 month(s) ago
Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer @WUSTLmed #gyncsm #oncology https://t.co/GDisEPIamY
-
-
Mashup Score: 3TG4001 Plus Avelumab Fails to Boost PFS in Recurrent/Metastatic, HPV16+ Cervical, Anogenital Tumors - 2 month(s) ago
The addition of TG4001 to avelumab failed to improve progression-free survival in HPV16-positive cervical and anogenital tumors.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
TG4001 Plus Avelumab Fails to Boost PFS in Recurrent/Metastatic, HPV16+ Cervical, Anogenital Tumors #gyncsm #oncology https://t.co/CiTGTBanel
-
-
Mashup Score: 7
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
CINtec PLUS Receives @WHO Endorsement in Cervical Cancer Prevention Guidelines #gyncsm #oncology https://t.co/oRJ6tkfpmE
-
-
Mashup Score: 7
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
CINtec PLUS Receives @WHO Endorsement in Cervical Cancer Prevention Guidelines #gyncsm #oncology https://t.co/oRJ6tkfpmE
-
-
Mashup Score: 6
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
CINtec PLUS Receives @WHO Endorsement in Cervical Cancer Prevention Guidelines #gyncsm #oncology https://t.co/oRJ6tkfpmE
-
-
Mashup Score: 5
NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
.@us_fda Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers #gyncsm #oncology https://t.co/1EUUmLkRSy
-
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer @GynCancerMD @MountSinaiMiami #gyncsm #oncology https://t.co/olsKM3lTeS